Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Chadarevian

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Presse Medicale (Paris, France : 1983)|October 30, 1998
[Lipids/hemostasis interactions. A new approach to cardiovascular risk factors]R Chadarevian, E Bruckert, G Turpin
Annales De Cardiologie Et D'Angeiologie|February 1, 1997
[Hypolipemic agents and prevention of coronary disease]R Chadarevian, E Bruckert, G Turpin
Journal of Cardiovascular Risk|October 26, 1999
Low free-thyroxine levels are a risk factor for subclinical atherosclerosis in euthyroid hyperlipidemic patientsE Bruckert, P Giral, R Chadarevian, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|January 15, 2000
Relationship between thyroid hormones and fibrinogen levelsR Chadarevian, E Bruckert, P Giral, et al.
La Revue Du Praticien|October 22, 1998
[Hyperlipoproteinemias. Epidemiology, etiology, physiopathology, diagnosis, treatment]R Chadarevian, P Cohen-Presberg, E Bruckert, et al.
Presse Medicale (Paris, France : 1983)|January 18, 1997
[Adrenal incidentalomas disclosing enzyme block in a 66-year-old man]G Turpin, V Jullien, S Dejager, et al.
Therapie|March 7, 2002
[Hepatotoxicity of a synthetic cortisol antagonist: OP'DDD (mitotane)]O Neuman, E Bruckert, R Chadarevian, et al.
Thrombosis Research|December 10, 1999
Relationship between triglycerides and factor VIIc and plasminogen activator inhibitor type-1: lack of threshold valueR Chadarevian, E Bruckert, S Dejager, et al.
Annales De Cardiologie Et D'Angeiologie|May 8, 2007
[Compared with atorvastatin at the dose of 10 mg per day rosuvastatin was more effective to reach an LDL goal of < 1.00 g/l in high cardiovascular risk patients (ARIANE study)]N Danchin, R Chadarevian, J L Gayet, et al.
The Journal of Clinical Endocrinology and Metabolism|February 7, 2001
Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidismR Chadarevian, E Bruckert, L Leenhardt, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Presse Medicale (Paris, France : 1983)|October 30, 1998
[Lipids/hemostasis interactions. A new approach to cardiovascular risk factors]R Chadarevian, E Bruckert, G Turpin
Annales De Cardiologie Et D'Angeiologie|February 1, 1997
[Hypolipemic agents and prevention of coronary disease]R Chadarevian, E Bruckert, G Turpin
Journal of Cardiovascular Risk|October 26, 1999
Low free-thyroxine levels are a risk factor for subclinical atherosclerosis in euthyroid hyperlipidemic patientsE Bruckert, P Giral, R Chadarevian, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|January 15, 2000
Relationship between thyroid hormones and fibrinogen levelsR Chadarevian, E Bruckert, P Giral, et al.
La Revue Du Praticien|October 22, 1998
[Hyperlipoproteinemias. Epidemiology, etiology, physiopathology, diagnosis, treatment]R Chadarevian, P Cohen-Presberg, E Bruckert, et al.
Presse Medicale (Paris, France : 1983)|January 18, 1997
[Adrenal incidentalomas disclosing enzyme block in a 66-year-old man]G Turpin, V Jullien, S Dejager, et al.
Therapie|March 7, 2002
[Hepatotoxicity of a synthetic cortisol antagonist: OP'DDD (mitotane)]O Neuman, E Bruckert, R Chadarevian, et al.
Thrombosis Research|December 10, 1999
Relationship between triglycerides and factor VIIc and plasminogen activator inhibitor type-1: lack of threshold valueR Chadarevian, E Bruckert, S Dejager, et al.
Annales De Cardiologie Et D'Angeiologie|May 8, 2007
[Compared with atorvastatin at the dose of 10 mg per day rosuvastatin was more effective to reach an LDL goal of < 1.00 g/l in high cardiovascular risk patients (ARIANE study)]N Danchin, R Chadarevian, J L Gayet, et al.
The Journal of Clinical Endocrinology and Metabolism|February 7, 2001
Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidismR Chadarevian, E Bruckert, L Leenhardt, et al.
Pageof 2